EL
Highly rated in
38
conditions

Dr. Eric J. Lowe

CKHD Main Hospital
Norfolk, VA
Highly rated in
38
conditions
Specialties:Pediatrics | Pediatric Hematology Oncology | Hematology Oncology
Experience:25 Years
Clinical Trials:Currently Recruiting for 32 Trials
Accepts:New PatientsMedicare
Highly rated in
38
conditions
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. Eric J. Lowe's experience treating your condition:
About Dr. Eric J. Lowe

Eric Lowe is a Pediatrics specialist and a Pediatric Hematologist Oncology expert in Norfolk, Virginia. Lowe has been practicing medicine for over 25 years and is highly rated in 38 conditions, according to our data. His top areas of expertise are Anaplastic Large Cell Lymphoma, Non-Hodgkin Lymphoma, Langerhans Cell Histiocytosis, Bone Marrow Aspiration, and Bone Marrow Transplant. He is licensed to treat patients in Virginia. Lowe is currently accepting new patients.

His clinical research consists of co-authoring 17 peer reviewed articles and participating in 95 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Eric J. Lowe it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. Eric J. Lowe accepts the following insurance:

  •  UnitedHealthcare
  •  HealthKeepers
  •  Optima Health
Call to see if your plan is accepted.
Locations
601 Childrens Ln, Norfolk, VA 23507
Background & Education
Graduate Institution
Emory University School Of Medicine, 1998
Specialties
Pediatrics
Pediatric Hematology Oncology
Hematology Oncology
Licenses
Pediatrics in VA
Hospital Affiliations
Childrens Hospital Of The Kings Daughters
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

93 Clinical Trials
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
Enrollment Status: Recruiting
Publish Date: December 15, 2022
Intervention Type: Other, Procedure, Drug
Study Drugs: CarboplatinSelumetinib SulfateVincristine Sulfate
Study Phase: Phase 3
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Enrollment Status: Recruiting
Publish Date: December 15, 2022
Intervention Type: Procedure, Drug, Biological, Radiation
Study Drugs: CyclophosphamideDoxorubicin HydrochlorideEtoposide PhosphateFilgrastimNivolumabPegfilgrastimPrednisolonePrednisoneRituximabRituximab+Hyaluronidase HumanVincristine Sulfate
Study Phase: Phase 3
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
Enrollment Status: Recruiting
Publish Date: December 15, 2022
Intervention Type: Other, Procedure, Drug
Study Drugs: CarboplatinSelumetinib SulfateVincristine Sulfate
Study Phase: Phase 3
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
Enrollment Status: Recruiting
Publish Date: December 15, 2022
Intervention Type: Drug, Biological, Radiation
Study Drugs: Erwinia AsparaginaseBlinatumomabCyclophosphamideCytarabineDexamethasoneDoxorubicin HydrochlorideLeucovorin CalciumMercaptopurineMethotrexatePegaspargasePrednisolonePrednisoneThioguanineVincristine Sulfate
Study Phase: Phase 3
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations
Enrollment Status: Recruiting
Publish Date: December 15, 2022
Intervention Type: Procedure, Drug
Study Drug: Selpercatinib
Study Phase: Phase 2
A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)
Enrollment Status: Recruiting
Publish Date: December 14, 2022
Intervention Type: Procedure, Radiation, Drug
Study Drugs: Dabrafenib MesylateTrametinib Dimethyl Sulfoxide
Study Phase: Phase 2
A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination With Vinblastine for Non-NF1, Non-TSC Patients With Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations
Enrollment Status: Recruiting
Publish Date: December 14, 2022
Intervention Type: Other, Procedure, Drug
Study Drugs: SelumetinibVinblastine
Study Phase: Phase 3
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations
Enrollment Status: Recruiting
Publish Date: December 13, 2022
Intervention Type: Procedure, Drug
Study Drug: Tipifarnib
Study Phase: Phase 2
A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
Enrollment Status: Recruiting
Publish Date: December 13, 2022
Intervention Type: Drug, Radiation, Procedure
Study Drug: Selinexor
Study Phase: Phase 1/Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of LY3023414 in Patients With Solid Tumors
Enrollment Status: Recruiting
Publish Date: December 09, 2022
Intervention Type: Procedure, Drug
Study Drug: Samotolisib
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations
Enrollment Status: Recruiting
Publish Date: December 08, 2022
Intervention Type: Drug
Study Drug: Ivosidenib
Study Phase: Phase 2
A Phase I Study With an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma
Enrollment Status: Recruiting
Publish Date: December 08, 2022
Intervention Type: Drug, Biological
Study Drugs: BrentuximabIpilimumabNivolumab
Study Phase: Phase 1/Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Enrollment Status: Recruiting
Publish Date: December 06, 2022
Intervention Type: Procedure, Drug, Other
Study Drugs: EnsartinibErdafitinibLarotrectinibOlaparibPalbociclibSamotolisibSelpercatinibSelumetinib SulfateTazemetostatTipifarnibUlixertinibVemurafenib
Study Phase: Phase 2
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Recruiting
Publish Date: December 06, 2022
Intervention Type: Drug, Other, Biological, Procedure
Study Drugs: AdavosertibAfatinibBinimetinibCapivasertibCopanlisibCrizotinibDabrafenibDasatinibDefactinibErdafitinibFGFR Inhibitor AZD4547IpatasertibLarotrectinibNivolumabOsimertinibPalbociclibPertuzumabPI3K-Beta Inhibitor GSK2636771SapanisertibSunitinibTaselisibTrametinibTrastuzumabUlixertinibVismodegib
Study Phase: Phase 2
Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias
Enrollment Status: Recruiting
Publish Date: December 05, 2022
Intervention Type: Procedure
A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
Enrollment Status: Recruiting
Publish Date: December 02, 2022
Intervention Type: Drug, Biological
Study Drugs: AxitinibNivolumab
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions
Enrollment Status: Recruiting
Publish Date: December 01, 2022
Intervention Type: Procedure, Drug
Study Drugs: LarotrectinibLarotrectinib Sulfate
Study Phase: Phase 2
StepByStep: A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors
Enrollment Status: Recruiting
Publish Date: November 30, 2022
Intervention Type: Other, Behavioral, Device
Study Phase: Phase 3
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
Enrollment Status: Recruiting
Publish Date: November 30, 2022
Intervention Type: Radiation, Drug, Procedure
Study Drugs: CarboplatinCyclophosphamideDoxorubicinEtoposideIfosfamideIrinotecanTopotecanVincristine
Study Phase: Phase 2
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
Enrollment Status: Recruiting
Publish Date: November 30, 2022
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: BleomycinBleomycin SulfateCarboplatinCisplatinEtoposideEtoposide Phosphate
Study Phase: Phase 3
A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular &Amp; Spinal Canal Irradiation (WVSCI) for Patients With Localized Non-Germinomatous Central Nervous System Germ Cell Tumor
Enrollment Status: Recruiting
Publish Date: November 30, 2022
Intervention Type: Drug, Biological, Procedure, Radiation, Other
Study Drugs: CarboplatinEtoposideFilgrastimIfosfamideMesnaPegfilgrastimThiotepa
Study Phase: Phase 2
A Prospective Phase 3 Study of Patients With Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma
Enrollment Status: Recruiting
Publish Date: November 30, 2022
Intervention Type: Drug, Radiation, Biological
Study Phase: Phase 3
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Enrollment Status: Recruiting
Publish Date: November 30, 2022
Intervention Type: Drug, Other, Procedure
Study Drugs: CarboplatinCisplatinDoxorubicinEtoposideFluorouracilGemcitabineIrinotecanOxaliplatinSorafenibVincristine Sulfate
Study Phase: Phase 2/Phase 3
Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)
Enrollment Status: Recruiting
Publish Date: November 30, 2022
Intervention Type: Other, Procedure, Drug
Study Drug: Tyrosine Kinase Inhibitor
Study Phase: Phase 2
A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
Enrollment Status: Recruiting
Publish Date: November 30, 2022
Intervention Type: Procedure, Other
Study Phase: Phase 3
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab With or Without Eflornithine (DFMO) in Children With Relapsed, Refractory or Progressive Neuroblastoma
Enrollment Status: Recruiting
Publish Date: November 30, 2022
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors
Enrollment Status: Recruiting
Publish Date: November 30, 2022
Intervention Type: Drug, Procedure
Study Drug: Memantine Hydrochloride
Study Phase: Phase 3
A Randomized Web-Based Physical Activity Intervention Among Children and Adolescents With Cancer
Enrollment Status: Recruiting
Publish Date: November 30, 2022
Intervention Type: Other, Device
Study Phase: Phase 3
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse
Enrollment Status: Recruiting
Publish Date: November 29, 2022
Intervention Type: Drug, Radiation, Biological
Study Drugs: BlinatumomabCyclophosphamideCytarabineDexamethasoneEtoposideHydrocortisone Sodium SuccinateLeucovorin CalciumMercaptopurineMethotrexateNivolumabPegaspargaseThioguanineVincristine Sulfate
Study Phase: Phase 2
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Enrollment Status: Recruiting
Publish Date: November 03, 2022
Intervention Type: Drug, Biological, Radiation, Other
Study Drugs: CalaspargaseCyclophosphamideCytarabineDaunorubicinDexamethasoneDoxorubicinInotuzumabLeucovorin6-MercaptopurineMethotrexatePegaspargasePrednisoloneThioguanineVincristine
Study Phase: Phase 3
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Enrollment Status: Recruiting
Publish Date: October 21, 2022
Intervention Type: Other
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Enrollment Status: Recruiting
Publish Date: October 21, 2022
Intervention Type: Drug, Other
Study Drugs: CarboplatinCyclophosphamideDoxorubicin HydrochlorideEtoposide
Study Phase: Phase 3
A Randomized Phase 2 Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL)
Enrollment Status: Active, not recruiting
Publish Date: December 15, 2022
Intervention Type: Drug
Study Drugs: Brentuximab VedotinCrizotinibCyclophosphamideCytarabineDexamethasoneDoxorubicin HydrochlorideEtoposideIfosfamideMethotrexate
Study Phase: Phase 2
A Safety, Pharmacokinetic and Efficacy Study of a y-Secretase Inhibitor, Nirogacestat (PF-03084014) in Children and Adolescents With Progressive, Surgically Unresectable Desmoid Tumors
Enrollment Status: Active, not recruiting
Publish Date: December 15, 2022
Intervention Type: Other, Drug
Study Drug: Nirogacestat
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate) in Patients With Tumors Harboring Activating MAPK Pathway Mutations
Enrollment Status: Active, not recruiting
Publish Date: December 13, 2022
Intervention Type: Drug, Other
Study Drugs: SelumetinibSelumetinib Sulfate
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Erdafitinib in Patients With Tumors Harboring FGFR1/2/3/4 Alterations
Enrollment Status: Suspended
Publish Date: December 13, 2022
Intervention Type: Procedure, Other, Drug
Study Drug: Erdafitinib
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations
Enrollment Status: Suspended
Publish Date: December 13, 2022
Intervention Type: Procedure, Other, Drug
Study Drug: Ensartinib
Study Phase: Phase 2
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
Enrollment Status: Active, not recruiting
Publish Date: December 07, 2022
Intervention Type: Drug, Other, Radiation
Study Drugs: ClofarabineCyclophosphamideCytarabineDasatinibDaunorubicin HydrochlorideDexamethasoneDoxorubicin HydrochlorideEtoposideHydrocortisone Sodium SuccinateLeucovorin CalciumMercaptopurineMethotrexatePegaspargasePrednisoneThioguanineVincristine Sulfate
Study Phase: Phase 3
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Enrollment Status: Active, not recruiting
Publish Date: December 06, 2022
Intervention Type: Other, Drug, Biological, Radiation
Study Drugs: BrentuximabDacarbazineDoxorubicinFilgrastimNivolumabPegfilgrastimVinblastine
Study Phase: Phase 3
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Enrollment Status: Active, not recruiting
Publish Date: December 06, 2022
Intervention Type: Drug, Procedure, Biological, Other, Radiation
Study Drugs: AsparaginaseBlinatumomabCyclophosphamideCytarabineDexamethasoneEtoposideLeucovorin CalciumMercaptopurineMethotrexateMitoxantroneMitoxantrone HydrochloridePegaspargaseHydrocortisoneThioguanineVincristineVincristine Sulfate
Study Phase: Phase 3
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Enrollment Status: Active, not recruiting
Publish Date: November 28, 2022
Intervention Type: Drug, Other
Study Drugs: CabozantinibCabozantinib-S-Malate
Study Phase: Phase 2
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Enrollment Status: Suspended
Publish Date: November 28, 2022
Intervention Type: Radiation, Drug, Biological, Other
Study Drugs: CyclophosphamideDactinomycinIrinotecan hydrochlorideTemsirolimusVincristine sulfateVinorelbine
Study Phase: Phase 3
Larotrectinib (LOXO-101, NSC# 788607) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias
Enrollment Status: Active, not recruiting
Publish Date: November 25, 2022
Intervention Type: Drug
Study Drug: Larotrectinib Sulfate
Study Phase: Phase 2
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Enrollment Status: Active, not recruiting
Publish Date: November 17, 2022
Intervention Type: Drug, Procedure, Biological, Radiation
Study Drugs: CyclophosphamideDoxorubicinDoxorubicin HydrochlorideEtoposideEtoposide PhosphateGanitumabIfosfamideVincristineVincristine Sulfate
Study Phase: Phase 3
A Phase 2 Study of Human-Mouse Chimeric Anti-disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab, NSC# 764038) in Combination With Sargramostim (GM-CSF) in Patients With Recurrent Osteosarcoma
Enrollment Status: Active, not recruiting
Publish Date: November 17, 2022
Intervention Type: Other, Biological
Study Drugs: DinutuximabSargramostim
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Tazemetostat in Patients With Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex
Enrollment Status: Active, not recruiting
Publish Date: November 17, 2022
Intervention Type: Drug
Study Drug: Tazemetostat
Study Phase: Phase 2
A Phase II Randomized Trial of Irinotecan/Temozolomide With Temsirolimus (NSC# 683864) or Chimeric 14.18 Antibody (Ch14.18) (NSC# 764038) in Children With Refractory, Relapsed or Progressive Neuroblastoma
Enrollment Status: Completed
Publish Date: October 24, 2022
Intervention Type: Drug, Biological, Other
Study Drugs: DinutuximabIrinotecan HydrochlorideSargramostimTemozolomideTemsirolimus
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients With Tumors Harboring Activating MAPK Pathway Mutations
Enrollment Status: Active, not recruiting
Publish Date: October 20, 2022
Intervention Type: Other, Drug
Study Drug: Ulixertinib
Study Phase: Phase 2
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Enrollment Status: Active, not recruiting
Publish Date: October 20, 2022
Intervention Type: Drug, Other
Study Drugs: AsparaginaseErwinia AsparaginaseCytarabineDaunorubicinEtoposideMitoxantroneThioguanine
Study Phase: Phase 3
A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations
Enrollment Status: Active, not recruiting
Publish Date: October 19, 2022
Intervention Type: Drug, Radiation
Study Drugs: TemozolomideVeliparib
Study Phase: Phase 2
View 18 Less Clinical Trials -
17 Total Publications
ALK inhibitors for ALK-altered paediatric malignancies.
Journal: The Lancet. Oncology
Published: October 17, 2021
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
LS
Dr. Lloyd A. Shabazz
Hematology Oncology | Hematology | Oncology
Highly rated in
69
conditions
Hematology Oncology
Hematology
Oncology

Bon Secours Health System

Bon Secours Maryview Medical Center Medical Oncology

7185 Harbour Towne Pkwy, 
Suffolk, VA 
 7.6 mi

Lloyd Shabazz is a Hematologist Oncology specialist and a Hematologist in Suffolk, Virginia. Shabazz has been practicing medicine for over 36 years and is highly rated in 69 conditions, according to our data. His top areas of expertise are Sickle Cell Disease, Myelodysplastic Syndrome (MDS), Iron Deficiency Anemia, and Paget Disease of the Breast. He is licensed to treat patients in Virginia. Shabazz is currently accepting new patients.

TA
Dr. Thomas A. Alberico
Hematology Oncology | Hematology | Oncology
Highly rated in
45
conditions
Hematology Oncology
Hematology
Oncology

Sentara Healthcare

Virginia Oncology Associates

5900 Lake Wright Dr, 
Norfolk, VA 
 5.5 mi

Thomas Alberico is a Hematologist Oncology specialist and a Hematologist in Norfolk, Virginia. Alberico has been practicing medicine for over 44 years and is highly rated in 45 conditions, according to our data. His top areas of expertise are Paget Disease of the Breast, Lung Cancer, Pleuropulmonary Blastoma, Inflammatory Breast Cancer, and Bone Marrow Aspiration. He is licensed to treat patients in Virginia. Alberico is currently accepting new patients.

MF
Dr. Mark T. Fleming
Hematology Oncology | Hematology | Oncology
Highly rated in
27
conditions
Hematology Oncology
Hematology
Oncology

Sentara Healthcare

Virginia Oncology Associates

3000 Coliseum Dr, 
Hampton, VA 
 14.3 mi

Mark Fleming is a Hematologist Oncology specialist and a Hematologist in Hampton, Virginia. Fleming has been practicing medicine for over 24 years and is highly rated in 27 conditions, according to our data. His top areas of expertise are Bladder Cancer, Familial Wilms Tumor 2, WT1-Related Wilms Tumor Syndromes, and Wilms Tumor. He is licensed to treat patients in Virginia. Fleming is currently accepting new patients.